CHEMOTHERAPY FOR ADVANCED THYMOMA - PRELIMINARY-RESULTS OF AN INTERGROUP STUDY

被引：47

作者：

LOEHRER, PJ

PEREZ, CA

ROTH, LM

GRECO, FA

LIVINGSTON, RB

EINHORN, LH

机构：

[1] EDWARD MALLINCKRODT INST RADIOL, DEPT RADIAT THERAPY, ST LOUIS, MO 63110 USA

[2] VANDERBILT UNIV, MED CTR N A-2127, NASHVILLE, TN 37232 USA

[3] UNIV WASHINGTON, DEPT ONCOL, SEATTLE, WA 98195 USA

来源：

ANNALS OF INTERNAL MEDICINE | 1990年 / 113卷 / 07期

关键词：

D O I：

10.7326/0003-4819-113-7-520

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Combination therapy with cisplatin, doxorubicin, and cyclophosphamide frequently produces objective remissions in patients with advanced thymoma. Further experience with this treatment regimen is warranted to clarify potential prognostic factors in patients with unresectable thymoma.

引用

页码：520 / 524

页数：5

共 50 条

[1] INVASIVE-CARCINOMA OF THE THYMUS - A MULTICENTER RETROSPECTIVE REVIEW OF 56 CASES [J].

ARRIAGADA, R ;

BRETEL, JJ ;

CAILLAUD, JM ;

GARRETA, L ;

GUERIN, RA ;

LAUGIER, A ;

LECHEVALIER, T ;

SCHLIENGER, M .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1984, 20 (01) :69-74

[2]

BATATA MA, 1974, CANCER, V34, P389, DOI 10.1002/1097-0142(197408)34:2<389::AID-CNCR2820340224>3.0.CO

[3]

2-Z

[4]

BONOMI P, 1988, P AN M AM SOC CLIN, V7, P221

[5]

BOSTON B, 1976, CANCER, V38, P49, DOI 10.1002/1097-0142(197607)38:1<49::AID-CNCR2820380109>3.0.CO

[6]

2-6

[7] A CONFIDENCE-INTERVAL FOR THE MEDIAN SURVIVAL-TIME [J].

BROOKMEYER, R ;

CROWLEY, J .

BIOMETRICS, 1982, 38 (01) :29-41

[8]

CAMPBELL MG, 1981, CANCER-AM CANCER SOC, V48, P1315, DOI 10.1002/1097-0142(19810915)48:6<1315::AID-CNCR2820480611>3.0.CO

[9]

2-2

[10]

CHAHINIAN AP, 1981, CANCER-AM CANCER SOC, V47, P1752, DOI 10.1002/1097-0142(19810401)47:7<1752::AID-CNCR2820470705>3.0.CO

← 1 2 3 4 5 →